Fernandez de Larrea et al. investigated the pattern of evolving M-protein as a risk predictor again with the new SMM diagnosis criteria devised by the IMWG in 2014 (BMPC% ≥ 60%, or FLCr ≥ 100 or >1 focal lesion is now defined as MM) and a larger cohort of patients [28]. Here, MYOM2 is linked to Miyoshi myopathy.